LC-MS/MS raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-07-08 and is reviewed periodically as new material appears.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA under peptide hormones |
| WADA class | S2 | Peptide hormones, growth factors, related substances, and mimetics |
| Approved therapeutic use | Not established | Clinical research did not lead to broad marketing approval |
| Common detection method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry |
| Sample preparation | Extraction and enrichment | Immunoaffinity or solid-phase extraction may be used |
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Saralasin ist ein medizinisches Präparat, das als Angiotensin II-Rezeptor-Antagonist fungiert. Es ist ein Peptid, das strukturelle Ähnlichkeiten mit Angiotensin II aufweist, jedoch antagonistische Eigenschaften hat. Es enthält wie Angiotensin Sarkosin-1 und Alanin-8 – daher der Name (Sarkosin, Alanin, Angiotensin). Der Wirkstoff spielt im Bereich der Hypertonie und der Aldosteronsekretion eine Rolle. In der Medizin wurde Saralasin hauptsächlich in Forschung und Entwicklung eingesetzt, insbesondere in Studien zur Untersuchung des Renin-Angiotensin-Systems, das eine wesentliche Rolle bei der Blutdruckregulation spielt. Saralasin bindet an Angiotensin II-Rezeptoren, verhindert jedoch die üblichen Wirkungen von Angiotensin II, wie Vasokonstriktion (Verengung der Blutgefäße) und Stimulierung der Aldosteronsekretion. Es wurde in den frühen Stadien der Entwicklung von Bluthochdruckmedikamenten verwendet, vor allem als Forschungsinstrument zur Beurteilung des Renin-Status und der Renin-Aktivität bei Hypertoniepatienten. Aufgrund seiner Peptidnatur und der Notwendigkeit der intravenösen Verabreichung ist Saralasin für die klinische Anwendung weniger praktikabel. Es wurde weitgehend durch nicht-peptidische, oral verfügbare AT1-Antagonisten ersetzt, die heute zur Behandlung von Hypertonie und anderen kardiovaskulären Erkrankungen eingesetzt werden. Diese neueren Medikamente bieten ähnliche therapeutische Wirkungen, sind jedoch patientenfreundlicher in der Anwendung.
== Literatur == Th. Philipp, H. Zschiedrich und A. Distler: Einfluß des Angiotensin II-Antagonisten Saralasin auf die Hämodynamik bei Patienten mit renovaskulärer Hypertonie. In: Klinische Wochenschrift. Band 55, Heft 18 / September 1977on-line Publikationen zu Saralasin
Sekretin (auch Secretin) ist ein gastrointestinales Peptidhormon. Beim Menschen stoppt Sekretin die Produktion der Magensäure und veranlasst das Pankreas, Natriumhydrogencarbonat-reiches Sekret abzugeben. Es gehört zur Glucagon-Familie von Peptidhormonen. Seine Vorstufe ist das sogenannte Prosekretin. Sekretin ist – nach dem Adrenalin – das zweite Hormon, das entdeckt wurde. William Bayliss und Ernest Starling fanden 1902 bei Experimenten mit dem im Zwölffingerdarm von ihnen entdeckten Sekretion zur Verdauung seine Funktion als Agens, das über das Blut die Pankreassekretion anregt, heraus und definierten 1905 den von einem Mitarbeiter der beiden Wissenschaftler vorgeschlagenen Begriff „Hormon“. Gebildet wird es in S-Zellen des Zwölffingerdarms. Der Stimulus zur Sekretion ist ein niedriger pH-Wert (unter 4,5) des Speisebreis im Zwölffingerdarm. Bei Fröschen wird es von spezifischen Zellen der Langerhans-Inseln der Bauchspeicheldrüse gebildet.
führt zu einer erhöhten Natriumhydrogencarbonat-Produktion (NaHCO3) in Bauchspeicheldrüse, Gallenblase und Dünndarm hemmt die Gastrin-Sekretion beim Gesunden bewirkt eine überschießende Gastrin-Sekretion beim Gastrinom (Zollinger-Ellison-Syndrom) führt zur Kontraktion der Gallenblase erhöht die Produktion von Muzinen in den Magenschleimhautzellen und verzögert somit die Magenentleerung stimuliert die Ausschüttung von Insulin und Somatostatin.
Sources: de.wikipedia.org
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.
Confirmatory detection typically uses liquid chromatography with mass spectrometry. Immunoassays may be used for screening, but mass spectrometry provides structural confirmation.
No widely approved therapeutic indication exists for AOD-9604. It has been investigated in clinical studies, but regulatory approvals for general medical use are not established.
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.